AAS
ZBIO icon

Ameritas Advisory Services’s Zenas BioPharma ZBIO Stock Holding History

Ameritas Advisory Services’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07K Buy
42
+36
+600% +$716 ﹤0.01% 1777
2026
Q1 		$117 Buy
+6
New +$135 ﹤0.01% 1056

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Ameritas Advisory Services's ZBIO Position: Q2 2026 in Review

Ameritas Advisory Services increased its Zenas BioPharma (ZBIO) stake by 600% in Q2 2026, buying an estimated $716 and bringing the position to 42 shares worth $1.07K. The position accounts for ﹤0.01% of the portfolio, ranked #1777.

Ameritas Advisory Services first reported a position in ZBIO in Q1 2026 and has held it in 2 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Ameritas Advisory Services held 42 shares of Zenas BioPharma worth $1.07K as of Q2 2026.
  • Ameritas Advisory Services bought 36 Zenas BioPharma shares in Q2 2026, an estimated $716.
  • Zenas BioPharma made up ﹤0.01% of Ameritas Advisory Services's portfolio in Q2 2026, its #1777 holding.
  • Ameritas Advisory Services first reported a position in Zenas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.